Latest news with #Novartis
Reuters
2 hours ago
- Business
- Reuters
US FDA approves Alcon's new dry-eye drug
May 28 (Reuters) - Eye-care drugmaker Alcon (ALCC.S), opens new tab said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED). Spun off from Novartis (NOVN.S), opens new tab in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of 2025 and beyond. The approval was based on late-stage studies in which the liquid medication, Tryptyr, demonstrated natural tear production as early as day one. The company said Tryptyr stimulates corneal sensory nerves to quickly increase natural tear production. DED is a condition in which the eyes either do not produce enough tears or produce poor-quality tears, leading to discomfort and potentially affecting vision. The company said about 38 million individuals in the United States suffer from DED, yet fewer than 10% of diagnosed patients are being treated with a prescription product. Alcon, which produces contact lenses, dry eye drops, gels and other related products, expects to launch Tryptyr in the United States during the third quarter of 2025, with plans to introduce the treatment in other markets later. Other FDA-approved treatments for DED include Alcon's Eysuvis and Bausch + Lomb's ( opens new tab Xiidra. Last month, however, the FDA declined to approve Aldeyra Therapeutics' (ALDX.O), opens new tab treatment for DED.
Business Wire
15 hours ago
- Business
- Business Wire
FranklinCovey Hosts Exclusive Live Webinar with Bestselling Authors, Amy Edmondson, Stephen M. R. Covey and Liz Wiseman on The Power of Leadership in Uncertain Times
SALT LAKE CITY--(BUSINESS WIRE)--FranklinCovey (NYSE: FC): Walker added, "Change isn't the exception, it's the rule. How organizations respond to disruptive moments along their journey will determine whether they simply endure the turbulence, or use it as a catalyst to evolve, adapt, and transform." Paul Walker, FranklinCovey CEO, said, 'When uncertainty hits, it doesn't remain outside an organization. It creeps inside into how leaders lead, how teams perform, and how organizations hold it together when nothing feels stable. Leaders are expected to move fast and stay decisive, without a playbook. Teams are expected to deliver more—with less clarity, less connection, and fewer resources.' To help organizations overcome these challenges, FranklinCovey is hosting an exclusive webinar with Edmondson, Covey and Wiseman for a provocative conversation that will explore the hidden costs of uncertainty and how today's best leaders are breaking through to become change agents during times of disruption. Walker added, 'Change isn't the exception, it's the rule. How organizations respond to disruptive moments along their journey will determine whether they simply endure the turbulence, or use it as a catalyst to evolve, adapt, and transform.' The panel of experts will explore the three barriers no leader can afford to ignore in these uncertain times: The Leadership Crisis: Why outdated leadership models are taxing performance and growth—and what leaders must do now to adapt. The Engagement Recession: How exhaustion, disconnection, and cultures of caution are negatively impacting performance and morale—and how leaders can reignite commitment and resilience. The Adaptability Dilemma: How over-analysis, misalignment, and chronic rigidity are stalling performance—and how great leaders move fast, build trust, and create clarity in times of disruption. ABOUT THE PRESENTERS: Amy C. Edmondson: Amy C. Edmondson is the Novartis Professor of Leadership and Management at the Harvard Business School, a chair established to support the study of human interactions that lead to the creation of successful enterprises that contribute to the betterment of society. Edmondson has been recognized by the biannual Thinkers50 global ranking of management thinkers since 2011, and most recently was ranked #1 in 2021 and 2023; she also received that organization's Breakthrough Idea Award in 2019, and Talent Award in 2017. She studies teaming, psychological safety, and organizational learning, and her articles have been published in numerous academic and management outlets, including Administrative Science Quarterly, Academy of Management Journal, Harvard Business Review, and California Management Review. Her 2019 book, The Fearless Organization: Creating Psychological Safety in the Workplace for Learning, Innovation and Growth (Wiley), has been translated into 15 languages. Edmondson's latest book, Right Kind of Wrong (Atria), builds on her prior work on psychological safety and teaming to provide a framework for thinking about, discussing, and practicing the science of failing well. First published in the US and in the UK (Penguin) in September 2023, the book is due to be translated into 24 additional languages and was selected for the Financial Times and Schroders Best Business Book of the Year award. Stephen M. R. Covey: Covey is a New York Times and #1 Wall Street Journal bestselling author of T he Speed of Trust and Trust & Inspire. He is the former CEO of Covey Leadership Center, which, under his stewardship, became the largest leadership development company in the world. Stephen personally led the strategy that propelled his father's book, Dr. Stephen R. Covey's The 7 Habits of Highly Effective People, to become one of the two most influential business books of the 20th Century, according to CEO Magazine. As president and CEO of Covey Leadership Center, Stephen nearly doubled revenues while increasing profits by 12 times. During that period, the company expanded throughout the world into over 40 countries, greatly increasing the value of the brand and enterprise. The company was valued at $2.4 million when Stephen was named CEO, and, within three years, he had grown shareholder value to $160 million in a merger he orchestrated with Franklin Quest to form FranklinCovey. Stephen co-founded CoveyLink, a consulting practice, which focuses on enabling leaders and organizations to increase and leverage trust to achieve superior performance. Stephen merged CoveyLink with FranklinCovey, forming the Global Speed of Trust Practice, where Stephen serves as global practice leader. Learn More Liz Wiseman: Wiseman is a researcher and executive advisor who teaches leadership to top organizations worldwide. She wrote the New York Times bestsellers Multipliers, The Multiplier Effect, and Wall Street Journal bestsellers Rookie Smarts and Impact Players. She is the CEO of the Wiseman Group, a leadership research and development firm headquartered in Silicon Valley, California. Some of her recent clients include Apple, AT&T, Disney, Meta, Google, Microsoft, Nike, Salesforce, Tesla, and X. Liz has received the top achievement award for leadership from Thinkers50. She has also been consistently named one of the world's leading 50 management thinkers in its bi-annual ranking. Liz has conducted significant research in leadership and talent development. She writes for Harvard Business Review, Fortune, and various other business and leadership journals and is a frequent guest lecturer at Brigham Young University and Stanford University. She is a former executive at Oracle, where she worked as the Vice President of Oracle University and the global leader for Human Resource Development. Liz holds a bachelor's degree in business management and a master's in organizational behavior from Brigham Young University. Learn More ABOUT FRANKLINCOVEY FranklinCovey (NYSE: FC) is one of the largest and most trusted leadership companies in the world, with directly owned and licensee partner offices providing professional services in over 160 countries and territories. The Company transforms organizations by partnering with clients to build leaders, teams, and cultures that get breakthrough results through collective action, which leads to a more engaging work experience for their people. Available through the FranklinCovey All Access Pass, FranklinCovey's best-in-class content, solutions, experts, technology, and metrics seamlessly integrate to ensure lasting behavior change at scale. Solutions are available in multiple delivery modalities in more than 20 languages. This approach to leadership and organizational change has been tested and refined by working with tens of thousands of teams and organizations over the past 30 years. Clients have included organizations in the Fortune 100, Fortune 500 and thousands of small and mid-sized businesses, numerous government entities, and educational institutions. To learn more, visit and enjoy exclusive content across FranklinCovey's social media channels at: LinkedIn, Facebook, Twitter, Instagram, and YouTube.
Yahoo
2 days ago
- Business
- Yahoo
Thin Film Drug Manufacturing Business Research Report 2025: Market to reach $23.8 Billion by 2030 - Growing Focus on Enhancing Bioavailability and Drug Absorption Strengthens Business
Key drivers include demand for innovative drug delivery systems and patient-centric formulations. Technological advancements and collaborations are enhancing manufacturing processes. Significant growth is expected in segments like Oral Thin Film, and regions such as the U.S. and China. Major players include Allergan, IntelGenx, and Novartis. This report offers comprehensive market data, trends, and strategic insights. Thin Film Drug Manufacturing Market Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Thin Film Drug Manufacturing - Global Strategic Business Report" report has been added to global market for Thin Film Drug Manufacturing was valued at US$15.4 Billion in 2024 and is projected to reach US$23.8 Billion by 2030, growing at a CAGR of 7.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Thin Film Drug Manufacturing market. The global adoption of thin film drug manufacturing is driven by the increasing demand for novel drug delivery systems and the growing need for patient-centric formulations. As the pharmaceutical industry continues to explore innovative approaches to enhance drug efficacy and improve patient experiences, thin film technologies are gaining traction. These formulations offer benefits such as faster onset of action, improved bioavailability, and reduced side effects. Moreover, thin films can be tailored to deliver a wide range of drugs, including poorly soluble compounds and biologics, thereby addressing challenges associated with traditional drug delivery methods. The focus on patient-centric solutions, combined with advancements in manufacturing technologies, is propelling the growth of the global thin film drug manufacturing market. What Is Driving the Growth of the Global Thin Film Drug Manufacturing Market?The growth in the global Thin Film Drug Manufacturing market is driven by several factors, including rising investments in research and development for advanced drug delivery technologies, increasing collaborations between pharmaceutical companies and research institutions, and the growing focus on personalized medicine and patient-centric formulations. One of the primary growth drivers is the rising investment in research and development aimed at creating innovative drug delivery systems that enhance therapeutic efficacy. Pharmaceutical companies are increasingly allocating resources to explore thin film technologies as a means to improve drug formulations and address challenges associated with traditional delivery methods. This focus on R&D is fostering innovation in thin film drug manufacturing, driving demand as companies seek to differentiate their products and improve patient significant driver of market growth is the increasing collaborations between pharmaceutical companies, biotech firms, and research institutions to advance thin film drug technologies. Collaborative efforts are essential for accelerating the development of new formulations, sharing expertise, and accessing cutting-edge technologies. These partnerships are fostering innovation in thin film drug manufacturing by enabling the pooling of resources and knowledge to overcome technical challenges and streamline the development process. The rise of collaborative initiatives is expected to enhance the pace of innovation in the thin film drug manufacturing sector, contributing to market the growing focus on personalized medicine and patient-centric formulations is supporting the growth of the thin film drug manufacturing market. As healthcare moves towards more tailored treatment approaches, there is a demand for drug delivery systems that can accommodate individual patient needs and preferences. Thin film formulations offer versatility in terms of dosing, formulation design, and delivery routes, making them suitable for personalized medicine applications. The emphasis on creating patient-centric solutions that enhance adherence and improve therapeutic outcomes is driving the adoption of thin film technologies in various therapeutic areas. This trend is particularly strong in areas such as pain management, where individualized treatment regimens are essential for optimal patient advancements in technology and manufacturing processes are shaping the growth of the thin film drug manufacturing market. The increasing availability of advanced manufacturing techniques, such as roll-to-roll processing and continuous manufacturing, is enabling the efficient production of thin films at scale. These innovations are reducing production costs and improving the quality and consistency of thin film formulations. As manufacturers leverage these technological advancements to enhance production capabilities, the adoption of thin film drug manufacturing is expected to rise. As these factors continue to influence the thin film drug manufacturing landscape, the market is poised for robust growth, driven by rising investments in R&D for advanced drug delivery technologies, increasing collaborations between pharmaceutical companies and research institutions, and a growing focus on personalized medicine and patient-centric formulations. What Factors Are Driving the Adoption of Thin Film Drug Manufacturing Across Various Pharmaceutical Segments?The adoption of thin film drug manufacturing is being driven by several key factors, including the increasing demand for innovative drug delivery systems, the rising prevalence of chronic diseases, and the growing focus on patient compliance and convenience. One of the primary drivers is the increasing demand for innovative drug delivery systems that provide improved therapeutic outcomes. As the pharmaceutical industry evolves, there is a significant push towards developing formulations that enhance bioavailability and improve the pharmacokinetic profiles of drugs. Thin film drug delivery systems meet these demands by offering rapid dissolution and absorption, allowing for faster onset of action and improved patient outcomes. The need for innovative delivery systems is driving the adoption of thin film technologies in various therapeutic areas, including pain management, cardiovascular diseases, and significant factor influencing the adoption of thin film drug manufacturing is the rising prevalence of chronic diseases that require long-term treatment and management. Chronic conditions, such as diabetes, hypertension, and cancer, often necessitate frequent dosing or complex treatment regimens, making patient adherence a critical issue. Thin film formulations provide a user-friendly alternative to traditional dosage forms, allowing patients to easily take their medication without the need for water or complex administration processes. This convenience is particularly beneficial for elderly patients and those with mobility challenges. The growing emphasis on improving patient adherence and outcomes in chronic disease management is driving the demand for thin film drug delivery the expanding applications of thin film drug manufacturing in emerging markets are driving their adoption across various pharmaceutical segments. As healthcare infrastructure improves and access to medications increases in developing regions, the demand for innovative drug delivery solutions is expected to rise. Manufacturers are exploring thin film technologies to cater to the specific needs of these markets, including the development of affordable and accessible formulations. The potential for thin films to address unmet medical needs in emerging markets is creating new opportunities for growth in the thin film drug manufacturing ScopeKey Insights: Market Growth: Understand the significant growth trajectory of the Oral Thin Film segment, which is expected to reach US$9.9 Billion by 2030 with a CAGR of a 7.5%. The Transdermal Thin Film segment is also set to grow at 8.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $4.3 Billion in 2024, and China, forecasted to grow at an impressive 7.3% CAGR to reach $3.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Allergan plc, Indivior plc, IntelGenx Corp., MonoSol Rx, Novartis AG and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 197 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $15.4 Billion Forecasted Market Value (USD) by 2030 $23.8 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Thin Film Drug Manufacturing - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Fast-Dissolving and Patient-Friendly Drug Delivery Systems Drives Growth of Thin Film Drug Manufacturing Increased Adoption of Thin Film Drugs in Pediatric and Geriatric Populations Expands Addressable Market Growing Focus on Enhancing Bioavailability and Drug Absorption Strengthens Business Case for Thin Film Drug Manufacturing Rising Adoption of Thin Film Drugs in Motion Sickness, Cough, and Cold Treatments Sets the Stage for Market Expansion Increased Use of Thin Film Drug Manufacturing in Over-the-Counter (OTC) Pharmaceuticals Bodes Well for Market Growth Expansion of Thin Film Drug Manufacturing in Nutraceuticals and Dietary Supplements Expands Market Opportunities Increased Adoption of Thin Film Drugs in Antidepressants and Anti-Anxiety Medications Strengthens Market Opportunities Surge in Demand for Thin Film Drug Delivery Solutions in Veterinary Medicine Fuels Market Demand Growing Use of Thin Film Drugs in Tobacco Cessation and Nicotine Replacement Therapy Expands Market Opportunities Technological Advancements in Buccal and Sublingual Film Delivery Methods Propel Market Growth FOCUS ON SELECT PLAYERS:Some of the 47 companies featured in this report Allergan plc Indivior plc IntelGenx Corp. MonoSol Rx Novartis AG Pfizer, Inc. Solvay Sumitomo Dainippon Pharma Co., Ltd. Wolters Kluwer ZIM Laboratories Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Thin Film Drug Manufacturing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Economic Times
2 days ago
- Business
- Economic Times
Novartis offers payment plan for high-cost heart medicine
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: In a first-of-its-kind pricing strategy in the pharmaceutical industry, Swiss drug major Novartis has introduced a financing scheme for its cholesterol lowering drug brand Sybrava (inclisiran) in India, as the company looks to expand the adoption of the new generation heart drug that has so far been restricted due to its high has tied up with Indian payment technology company Pine Labs to offer a monthly instalment scheme for the twice-a-year treatment of the injectable drug used to reduce levels of low-density lipoprotein cholesterol (LDL-C), commonly called bad cholesterol."We have recently launched a zero-interest EMI scheme with Pine Labs so that this treatment can be accessible to more patients," Amitabh Dube, country president & MD, Novartis India, said in an exclusive interview with instalment is priced at Rs 15,000-16,000. "The first is a loading dose and the second dose is after 90 days, and then after 180 days. It will be a rolling cycle," said per cardiologists, Novartis has come up with a one-on-one scheme where the second injection will be free on purchase of the first a patient has to pay full value of the first dosage through equated monthly drug was priced at Rs 1.2 lakh per injection when it was launched in January 2024. In the US, sold under brand Leqvio, it is priced at $3,373.4 per dose (about Rs 2.9 lakh).More than 3,000 patients have currently been put on the drug in expand the reach for inclisiran, Novartis has also entered into marketing tie-ups with Mankind Pharma , JB Pharma and Lupin Mankind, which sells inclisiran under brand Crenzlo, is also evaluating possibilities in terms of patient assistance programmes that can make the drug more affordable to the eligible patients in India, said Atish Majumdar, senior president-sales and marketing. Lupin has launched the drug under Tilpazan, while JB Pharma's brand is and JB Pharma did not respond to ET's query until press time on the one year since April 2024, inclisiran recorded sales of Rs 7.7 crore among all three partners, according to data from is not a replacement for statins, the most commonly used class of medications to lower cholesterol, but can be recommended as a line of treatment when statins do not work or if a person is statin intolerant. However, top cardiologists are divided over the widespread prescribing of the opine it is another addition to their armament of treatment. "It is a very important drug that has come into the market. It has the potential to be a very big game changer for blockages," said Dr Nihar Mehta, associate director, Department of Structural Heart Diseases, Jaslok Hospital & Research others said its usage will be for a limited number of patients. Dr Ganesh Kumar AV, director of cardiology at LH Hiranandani Hospital Powai in Mumbai, said: "The medicine is good but it is being overused. With the right usage there are not many patients who need it. My usage of inclisiran has not been much over the last one year; maybe less than 10 out of the about 2,000 patients with coronary artery diseases I treated".
Time of India
2 days ago
- Business
- Time of India
Novartis offers payment plan for high-cost heart medicine
Mumbai: In a first-of-its-kind pricing strategy in the pharmaceutical industry, Swiss drug major Novartis has introduced a financing scheme for its cholesterol lowering drug brand Sybrava (inclisiran) in India, as the company looks to expand the adoption of the new generation heart drug that has so far been restricted due to its high pricing. Novartis has tied up with Indian payment technology company Pine Labs to offer a monthly instalment scheme for the twice-a-year treatment of the injectable drug used to reduce levels of low-density lipoprotein cholesterol (LDL-C), commonly called bad cholesterol. "We have recently launched a zero-interest EMI scheme with Pine Labs so that this treatment can be accessible to more patients," Amitabh Dube, country president & MD, Novartis India, said in an exclusive interview with ET. Each instalment is priced at Rs 15,000-16,000. "The first is a loading dose and the second dose is after 90 days, and then after 180 days. It will be a rolling cycle," said Dube. As per cardiologists, Novartis has come up with a one-on-one scheme where the second injection will be free on purchase of the first dose. However, a patient has to pay full value of the first dosage through equated monthly instalment. The drug was priced at Rs 1.2 lakh per injection when it was launched in January 2024. In the US, sold under brand Leqvio, it is priced at $3,373.4 per dose (about Rs 2.9 lakh). More than 3,000 patients have currently been put on the drug in India. To expand the reach for inclisiran, Novartis has also entered into marketing tie-ups with Mankind Pharma , JB Pharma and Lupin . Mankind, which sells inclisiran under brand Crenzlo, is also evaluating possibilities in terms of patient assistance programmes that can make the drug more affordable to the eligible patients in India, said Atish Majumdar, senior president-sales and marketing. Lupin has launched the drug under Tilpazan, while JB Pharma's brand is Izirize. Lupin and JB Pharma did not respond to ET's query until press time on Monday. In the one year since April 2024, inclisiran recorded sales of Rs 7.7 crore among all three partners, according to data from PharmaTrac. Inclisiran is not a replacement for statins, the most commonly used class of medications to lower cholesterol, but can be recommended as a line of treatment when statins do not work or if a person is statin intolerant. However, top cardiologists are divided over the widespread prescribing of the drug. Some opine it is another addition to their armament of treatment. "It is a very important drug that has come into the market. It has the potential to be a very big game changer for blockages," said Dr Nihar Mehta, associate director, Department of Structural Heart Diseases, Jaslok Hospital & Research Centre. However, others said its usage will be for a limited number of patients. Dr Ganesh Kumar AV, director of cardiology at LH Hiranandani Hospital Powai in Mumbai, said: "The medicine is good but it is being overused. With the right usage there are not many patients who need it. My usage of inclisiran has not been much over the last one year; maybe less than 10 out of the about 2,000 patients with coronary artery diseases I treated".
